Using three varieties of Brassica campestris, Hauarad (708), Maoshan-3 (714) and Youbai (715),as the maternal plants and one variety of Brassica oleracea Jingfeng-1 (6012) as paternalplants, crosses were made to produ...Using three varieties of Brassica campestris, Hauarad (708), Maoshan-3 (714) and Youbai (715),as the maternal plants and one variety of Brassica oleracea Jingfeng-1 (6012) as paternalplants, crosses were made to produce interspecific hybrids through ovary culture techniques.The ovaries from the cross between B. campestrisB.oleracea (7086012 and 7146012) werecultured and ovary culture was more effective in terms of obtained seeds when ovaries werecultured in vitro at 9 d after pollination (DAP). While for the cross of 7156012, it wasbetter when ovaries in vitro cultured at 12 DAP. Among three cross combinations, the cross of7146012 showed the best response and 43 seeds per ovary were obtained. Among the mediastudied, the ovaries from the cross of 7086012 cultured on MS media supplemented with 3.0 mgL-1 BA0.1 mg L-1 NAA showed better response, and its rate of seeds per ovary reached 44.0%.While the ovaries from the other two crosses (7146012 and 7156012) showed the best responsewhen cultured on B5 media supplemented with 3.0 mg L-1 BA + 0.2 mg L-1 NAA, and the rates of seedsper ovary reached 72.0 and 60.0%, respectively. All seeds obtained from the three crosscombinations were cultured on the MS media supplemented with 1.0 mg L-1 BA + 0.05 mg L-1 NAA,and the seeds from the cross of 7156012 showed the best germination response and thepercentage of germinations reached 66.7%. The regenerated plantlets were obtained from theseseedlings after cultured on the MS media supplemented with 0.05 mg L-1 NAA. Cytological studyshowed that these regenerated plants were all true hybrids of B.campestrisB.oleracea.展开更多
在非霍奇金淋巴瘤(non-Hodgkin's lymphoma,NHL)中,弥漫大B细胞淋巴瘤(diffuse large B cell lymphoma,DLBCL)的发生率最高,其异质性明显。利妥昔单抗的出现极大改善了患者的预后及生存,其联合CHOP成为经典一线治疗方案,50%~70%患...在非霍奇金淋巴瘤(non-Hodgkin's lymphoma,NHL)中,弥漫大B细胞淋巴瘤(diffuse large B cell lymphoma,DLBCL)的发生率最高,其异质性明显。利妥昔单抗的出现极大改善了患者的预后及生存,其联合CHOP成为经典一线治疗方案,50%~70%患者可治愈,但仍有30%~50%因耐药等原因反应差或在缓解后复发。复发难治DLBCL,尤其是无法自体造血干细胞移植或移植后复发病人的治疗是目前亟待解决的问题。随着对靶向免疫治疗研究的不断深入,许多药物不断进入临床应用或正在开发中,该文主要就单克隆抗体、双特异性抗体、抗体药物偶联物、选择性核出口蛋白抑制剂、嵌合抗原受体T细胞、程序性死亡受体/配体1抑制剂等药物作一简要综述。展开更多
基金supported by the Science and Technology Department of Zhej iang Province(021102109)Hangzhou Municipality(2003132E32)China-Sweden Cooperation Project(C08).
文摘Using three varieties of Brassica campestris, Hauarad (708), Maoshan-3 (714) and Youbai (715),as the maternal plants and one variety of Brassica oleracea Jingfeng-1 (6012) as paternalplants, crosses were made to produce interspecific hybrids through ovary culture techniques.The ovaries from the cross between B. campestrisB.oleracea (7086012 and 7146012) werecultured and ovary culture was more effective in terms of obtained seeds when ovaries werecultured in vitro at 9 d after pollination (DAP). While for the cross of 7156012, it wasbetter when ovaries in vitro cultured at 12 DAP. Among three cross combinations, the cross of7146012 showed the best response and 43 seeds per ovary were obtained. Among the mediastudied, the ovaries from the cross of 7086012 cultured on MS media supplemented with 3.0 mgL-1 BA0.1 mg L-1 NAA showed better response, and its rate of seeds per ovary reached 44.0%.While the ovaries from the other two crosses (7146012 and 7156012) showed the best responsewhen cultured on B5 media supplemented with 3.0 mg L-1 BA + 0.2 mg L-1 NAA, and the rates of seedsper ovary reached 72.0 and 60.0%, respectively. All seeds obtained from the three crosscombinations were cultured on the MS media supplemented with 1.0 mg L-1 BA + 0.05 mg L-1 NAA,and the seeds from the cross of 7156012 showed the best germination response and thepercentage of germinations reached 66.7%. The regenerated plantlets were obtained from theseseedlings after cultured on the MS media supplemented with 0.05 mg L-1 NAA. Cytological studyshowed that these regenerated plants were all true hybrids of B.campestrisB.oleracea.
文摘在非霍奇金淋巴瘤(non-Hodgkin's lymphoma,NHL)中,弥漫大B细胞淋巴瘤(diffuse large B cell lymphoma,DLBCL)的发生率最高,其异质性明显。利妥昔单抗的出现极大改善了患者的预后及生存,其联合CHOP成为经典一线治疗方案,50%~70%患者可治愈,但仍有30%~50%因耐药等原因反应差或在缓解后复发。复发难治DLBCL,尤其是无法自体造血干细胞移植或移植后复发病人的治疗是目前亟待解决的问题。随着对靶向免疫治疗研究的不断深入,许多药物不断进入临床应用或正在开发中,该文主要就单克隆抗体、双特异性抗体、抗体药物偶联物、选择性核出口蛋白抑制剂、嵌合抗原受体T细胞、程序性死亡受体/配体1抑制剂等药物作一简要综述。
